Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Altman Z2-Score: 6.14 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score?

Sichuan Kelun-Biotech Biopharmaceutical Co HKSE:06990 -2.79% 44 Altman Z2-Score is 6.14 as of Aug. 24, 2026. GuruFocus rates HKSE:06990 with a GF Score™ of 44/100 and a GF Value™ of HK$254.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,371 Biotechnology companies, Sichuan Kelun-Biotech Biopharmaceutical Co ranks better than 74.62% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Sichuan Kelun-Biotech Biopharmaceutical Co has a Altman Z2-Score of 6.14, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score or its related term are showing as below:

HKSE:06990' s Altman Z2-Score Range Over the Past 10 Years
Min: -44.11   Med: -3.72   Max: 6.14
Current: 6.14

During the past 5 years, Sichuan Kelun-Biotech Biopharmaceutical Co's highest Altman Z2-Score was 6.14. The lowest was -44.11. And the median was -3.72.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score Related Terms


Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
-44.11 -40.40 0.74 4.22 6.14

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.22 0.00 6.14 0.00

HKSE:06990 vs VRTX, REGN, RVMD: Altman Z2-Score Comparison

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score falls into.


HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.692+3.26*-0.7857+6.72*-0.0584+1.05*4.3399
=6.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was HK$6,616 Mil.
Total Current Assets was HK$5,688 Mil.
Total Current Liabilities was HK$1,110 Mil.
Retained Earnings was HK$-5,198 Mil.
Pre-Tax Income was HK$-393 Mil.
Interest Expense was HK$-7 Mil.
Total Liabilities was HK$1,239 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5687.826 - 1109.69)/6615.696
=0.692

X2=Retained Earnings/Total Assets
=-5197.79/6615.696
=-0.7857

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-393.039 - -6.803)/6615.696
=-0.0584

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(5376.775 - 0)/1238.922
=4.3399

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Sichuan Kelun-Biotech Biopharmaceutical Co has a Altman Z2-Score of 6.14 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 6.14 mean?
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Altman Z2-Score of 6.14 as of Aug. 24, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #348 out of 1371 companies in the Biotechnology industry, placing it in the top 25.4%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Altman Z2-Score is 6.14. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #348 out of 1371 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #348 out of 1371 companies for Altman Z2-Score. This puts Sichuan Kelun-Biotech Biopharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. Sichuan Kelun-Biotech Biopharmaceutical Co's current Altman Z2-Score is 6.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Altman Z2-Score is 6.14. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Altman Z2-Score is 6.14 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Altman Z2-Score: 6.14
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value